Therefore, co-targeting IGF-1R and IR for ubiquitination and degradation by well-designed engineered ubiquitin ligase represent an alternative therapeutic strategy for the treatment of cancers co-expressing IGF-1R/IR. Here, INSR is linked to cancer.